Skip Navigation
National Institutes of Health: National Cancer Institute: Division of Cancer Control and Population Sciences
Grant Details

Grant Number: 5R01CA160744-02 Interpret this number
Primary Investigator: Kim, Jane
Organization: Harvard School Of Public Health
Project Title: Comparative and Cost-Effectiveness of Preventing HPV-Related Diseases
Fiscal Year: 2013
Back to top


Abstract

DESCRIPTION (provided by applicant): Each year, more than 25,000 cases of invasive cancer attributable to human papillomavirus (HPV) infection occur in the United States; nearly 50% are cervical cancer, while the rest involve the oral cavity/oropharynx, anus, vulva, penis, and vagina. Collectively, these account for substantial morbidity and mortality, contribute to health disparities, and are associated with high economic costs. Advancements in HPV-related cancer epidemiology, coupled with new (e.g., HPV-16,-18 vaccines, HPV DNA testing) and emerging (e.g., biomarkers, therapeutic vaccines) technologies provide a remarkable opportunity to improve cancer prevention efforts. However, critical challenges remain with respect to clinical decision-making and prevention policy, pertaining to knowledge gaps and heterogeneities in the natural history of different cancers, uncertainties in HPV type distribution following HPV-16,-18 vaccination, and the real-world clinical effectiveness of emerging technologies. We propose to employ a decision-analytic approach, developing a flexible modeling framework that will allow us to synthesize the best available data; evaluate the health and economic consequences of alternative strategies; explore the uncertainty around their outcomes; explicitly quantify the tradeoffs associated with different approaches; and inform timely clinical and policy questions. By achieving our aims, we expect to have an impact on (1) the analytic methods of decision science; (2) the equitable distribution and rationale use of new technology; (3) the effectiveness of strategies for cancer prevention through clinical guidelines and national policies; (4) HPV-related cancer outcomes, including reduced incidence, enhanced quality of life, improved survival, and reduced disparities; and (5) the financial and economic profile of delivering cancer-related health services.

Back to top


Publications

Modeling Preventative Strategies Against Human Papillomavirus-related Disease In Developed Countries
Authors: Canfell K. , Chesson H. , Kulasingam S.L. , Berkhof J. , Diaz M. , Kim J.J. .
Source: Vaccine, 2012-11-20 00:00:00.0; 30 Suppl 5, p. F157-67.
PMID: 23199959
Related Citations

Cost-effectiveness Of Surveillance Strategies After Treatment For High-grade Anal Dysplasia In High-risk Patients
Authors: Assoumou S.A. , Mayer K.H. , Panther L. , Linas B.P. , Kim J. .
Source: Sexually Transmitted Diseases, 2013 Apr; 40(4), p. 298-303.
PMID: 23486494
Related Citations

Comprehensive Control Of Human Papillomavirus Infections And Related Diseases
Authors: Bosch F.X. , Broker T.R. , Forman D. , Moscicki A.B. , Gillison M.L. , Doorbar J. , Stern P.L. , Stanley M. , Arbyn M. , Poljak M. , et al. .
Source: Vaccine, 2013-11-22 00:00:00.0; 31 Suppl 8, p. I1-31.
PMID: 24229716
Related Citations

Comprehensive Control Of Human Papillomavirus Infections And Related Diseases
Authors: Bosch F.X. , Broker T.R. , Forman D. , Moscicki A.B. , Gillison M.L. , Doorbar J. , Stern P.L. , Stanley M. , Arbyn M. , Poljak M. , et al. .
Source: Vaccine, 2013-12-29 00:00:00.0; 31 Suppl 5, p. F1-31.
PMID: 24331745
Related Citations

Comprehensive Control Of Human Papillomavirus Infections And Related Diseases
Authors: Bosch F.X. , Broker T.R. , Forman D. , Moscicki A.B. , Gillison M.L. , Doorbar J. , Stern P.L. , Stanley M. , Arbyn M. , Poljak M. , et al. .
Source: Vaccine, 2013-12-30 00:00:00.0; 31 Suppl 6, p. G1-31.
PMID: 24331817
Related Citations

Comprehensive Control Of Human Papillomavirus Infections And Related Diseases
Authors: Bosch F.X. , Broker T.R. , Forman D. , Moscicki A.B. , Gillison M.L. , Doorbar J. , Stern P.L. , Stanley M. , Arbyn M. , Poljak M. , et al. .
Source: Vaccine, 2013-12-31 00:00:00.0; 31 Suppl 7, p. H1-31.
PMID: 24332295
Related Citations

The Value Of Improving Failures Within A Cervical Cancer Screening Program: An Example From Norway
Authors: Burger E.A. , Kim J.J. .
Source: International Journal Of Cancer, 2014-10-15 00:00:00.0; 135(8), p. 1931-9.
PMID: 24615416
Related Citations

Prevention Of Hpv-related Cancers In Norway: Cost-effectiveness Of Expanding The Hpv Vaccination Program To Include Pre-adolescent Boys
Authors: Burger E.A. , Sy S. , Nygård M. , Kristiansen I.S. , Kim J.J. .
Source: Plos One, 2014; 9(3), p. e89974.
PMID: 24651645
Related Citations

Practice-based Evidence For Primary Hpv Testing In The United States
Authors: Kim J.J. .
Source: Journal Of The National Cancer Institute, 2014 Aug; 106(8), .
PMID: 25038468
Related Citations

Too Late To Vaccinate? The Incremental Benefits And Cost-effectiveness Of A Delayed Catch-up Program Using The 4-valent Human Papillomavirus Vaccine In Norway
Authors: Burger E.A. , Sy S. , Nygård M. , Kristiansen I.S. , Kim J.J. .
Source: The Journal Of Infectious Diseases, 2015-01-15 00:00:00.0; 211(2), p. 206-15.
PMID: 25057044
Related Citations

Cervical Cancer Screening In Low-resource Settings: A Cost-effectiveness Framework For Valuing Tradeoffs Between Test Performance And Program Coverage
Authors: Campos N.G. , Castle P.E. , Wright T.C. , Kim J.J. .
Source: International Journal Of Cancer, 2015-11-01 00:00:00.0; 137(9), p. 2208-19.
PMID: 25943074
Related Citations